ClinicalTrials.gg
Not yet recruitingNCT06912191Updated Apr 4, 2025

Investigating How the RECT Impacts Brain Functional States Through the ACC-cerebellar Loop

An interventional study of Left cerebellar TMS stimulation combined with the RECT task and Right cerebellar TMS stimulation combined with the RECT task in Post-stroke Depression, sponsored by The Second Affiliated Hospital of Kunming Medical University. Not yet recruiting. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by The Second Affiliated Hospital of Kunming Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Experiment1: Using a brain EEG-TMS combined system, researchers aim to investigate the impact of the rostral anterior cingulate cortexr (rACC)-engaging cognitive task (RECT) combined single-pulse TMS magnetic stimulation on theta neural oscillations in the medial frontal lobe. The study will be divided into 4 groups: the first group will receive left cerebellar single-pulse TMS stimulation combined with the RECT task, the second group will receive right cerebellar single-pulse TMS stimulation combined with the RECT task, the third group will receive midline cerebellar single-pulse TMS stimulation combined with the RECT task, and the fourth group will receive sham cerebellar single-pulse TMS stimulation combined with the RECT task. Divide the participants into groups of 15 people each, following a 1:1:1:1 ratio. Based on the above testing, the stimulus method that results in the most significant change in the midline of the frontal lobe will be identified.

Experiment 2: Based on the research from Experiment 1, the most significant approach affecting theta neural oscillations in the medial frontal gyrus will be identified. This stimulation protocol will be combined with left dorsolateral prefrontal cortex iTBS stimulation in Experiment 2. The research aim of Experiment 2 is to investigate the most effective stimulation method for enhancing midline theta neural oscillations in the frontal lobe, in combination with left dorsolateral prefrontal cortex iTBS, for the treatment of post-stroke depression patients. This study will include 40 post-stroke depressed patients, and each participant must meet the inclusion criteria. The first group of participants, consisting of 20 individuals, will receive the optimal combination intervention. The second group of participants will only receive iTBS stimulation, without any additional intervention strategies used in Experiment 1. Patients will undergo Hamilton Depression Scale assessment and resting state and task state EEG collection at baseline, one week after intervention, and two weeks after intervention.The primary outcome will be the Hamilton Depression Scale, with EEG-related data being analyzed as a secondary outcome. Task-oriented EEG detection will include both facial expression recognition paradigm and oddball experiment paradigm. Reaction time, accuracy, and completion status will be recorded simultaneously in the experiment. The experiment will record patients' tolerance and any adverse events that occur.

02

Conditions studied

  • Post-stroke Depression

Keywords

  • EEG
  • ERP
03

In context

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 100 is above the median of 81 across 7,089 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

The Second Affiliated Hospital of Kunming Medical University is the lead sponsor of 17 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Onset of stroke \<6 months ago, or >6 months since the last stroke event;
  • Age >=18 years and \<85 years (as the probability of Vascular Cognitive Impairment increases above 85);
  • Patients with damage in the middle cerebral artery territory;
  • NIHSS >4 and \<26;
  • mRS score >=2;
  • Completion of CT or MRI;
  • No neurological or psychiatric disorders; no impairment of consciousness; able to comply with relevant treatments; no severe cognitive dysfunction ( >=15);
  • All participants are right-handed; Sign the form.

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy or psychiatric disorders (including depression, anxiety, or schizophrenia);
  • Severe comorbidities;
  • History of medication use: benzodiazepines, baclofen, antidepressants;
  • Non-compliance with the treatment plan;
  • Acute-phase cerebral hemorrhage, acute infectious diseases;
  • Severe suicidal tendencies in individuals with depression;
  • Individuals suffering from severe headaches, high blood pressure, malignant tumors, open wounds, vascular embolism, leukopenia, etc.;
  • Severe alcohol abuse;
  • History of cranial surgery, individuals with metal implants in the brain;
  • Individuals with an implanted cardiac pacemaker;
  • NIHSS >26, \<15;
  • Any disease likely to prevent the patient from surviving more than one month;
  • Pregnant individuals.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    LC TMS combined with the RECT task (Experiment1)

    Left cerebellar single-pulse TMS stimulation combined with the RECT task

    Other: Left cerebellar TMS stimulation combined with the RECT task

  • Experimental
    RC TMS combined with the RECT task (Experiment1)

    Right cerebellar single-pulse TMS stimulation combined with the RECT task

    Other: Right cerebellar TMS stimulation combined with the RECT task

  • Experimental
    MC TMS combined with the RECT task (Experiment1)

    Midline cerebellar single-pulse TMS stimulation combined with the RECT task

    Other: Midline cerebellar TMS stimulation combined with the RECT task

  • Sham comparator
    Sham cerebellar single-pulse TMS stimulation combined with the RECT task (Experiment1)

    Sham cerebellar single-pulse TMS stimulation combined with the RECT task, The TMS coil was placed at the cerebellar site but tilted 90° to prevent effective magnetic field penetration.

    Other: Sham cerebellar TMS stimulation combined with the RECT task

  • Experimental
    Combined Stimulus Intervention group (Experiment 2)

    Combined iTBS stimulation of the dorsolateral prefrontal cortex and TMS of the cerebellum with the RECT task intervention group

    Other: The best stimulation protocol combined with left dorsolateral prefrontal cortex iTBS

  • Experimental
    iTBS treatment group(Experiment 2)

    The group of participants will receive left dorsolateral prefrontal cortex iTBS stimulation, as well as sham cerebellar TMS stimulation and sham RECT task.

    Other: Left dorsolateral prefrontal cortex iTBS stimulation, as well as sham TMS stimulation and sham RECT task.

  • Sham comparator
    Traditional treatment group(Experiment 2)

    The group of participants will receive sham left dorsolateral prefrontal cortex iTBS stimulation, sham cerebellar TMS stimulation, and sham RECT task.

    Other: Sham left dorsolateral prefrontal cortex iTBS stimulation, sham cerebellar TMS stimulation, and sham RECT task.

Interventions

  • OtherLeft cerebellar TMS stimulation combined with the RECT task

    The first group will receive left cerebellar single-pulse TMS stimulation combined with the RECT task. RECT refers to rostral anterior cingulate cortexr (rACC)-engaging cognitive task. The theoretical basis of this task is that when subjects are in a state of focused attention, the power of theta neural oscillations in the midline of their frontal lobe will increase. By considering the features of post-stroke depression, this study combines the emotional recognition task with the RECT task. During each trial, individuals will view 4 faces consecutively, each displaying a different expression, and they will be required to memorize the sequence of expressions. Emoticons consist of joy, sorrow, and rage. After displaying four facial expressions, a brief text flowchart will appear. Participants need to check if the sequence reflected in the flowchart matches the order in which the four facial expressions appeared. If they match, click the left mouse button; if they do not match, click the

    Also known as: RECT task, TMS

  • OtherRight cerebellar TMS stimulation combined with the RECT task

    Right cerebellar single-pulse TMS stimulation combined with the RECT task

    Also known as: RECT task, TMS

  • OtherMidline cerebellar TMS stimulation combined with the RECT task

    Midline cerebellar single-pulse TMS stimulation combined with the RECT task

    Also known as: RECT task, TMS

  • OtherSham cerebellar TMS stimulation combined with the RECT task

    Sham cerebellar single-pulse TMS stimulation combined with the RECT task, The TMS coil was placed at the cerebellar site but tilted 90° to prevent effective magnetic field penetration.

    Also known as: RECT task

  • OtherThe best stimulation protocol combined with left dorsolateral prefrontal cortex iTBS

    The optimal stimulation protocol determined in Experiment 1 combined with stimulation of the left dorsolateral prefrontal cortex.

    Also known as: left dorsolateral prefrontal cortex iTBS, RECT task, TMS

  • OtherLeft dorsolateral prefrontal cortex iTBS stimulation, as well as sham TMS stimulation and sham RECT task.

    Subjects in the group underwent left dorsolateral prefrontal cortex iTBS stimulation, in addition to receiving sham TMS stimulation and participating in a sham RECT task. The sham RECT task involves having participants watch a continuous scroll of faces without needing to react.

    Also known as: left dorsolateral prefrontal cortex iTBS

  • OtherSham left dorsolateral prefrontal cortex iTBS stimulation, sham cerebellar TMS stimulation, and sham RECT task.

    The participants in this group received sham left dorsolateral prefrontal cortex iTBS stimulation, sham cerebellar TMS stimulation, and sham RECT task.

06

What researchers measure

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale,MADRS

    This scale will be the primary outcome measure for Experiment 2. Montgomery-Asberg Depression Rating Scale,MADRS: Extreme depression: MADRS \>35; Major depression: MADRS \>30; Moderate depression: MADRS \>22; Mild depression: MADRS \>12; Remission stage: MADRS \<12.

    Time frame: Day1

  2. Electroencephalogram

    EEG will be the main outcome measures for Experiment 1 and Experiment 2. EEG power in the delta, theta, alpha, beta band: the power spectral density (PSD) in unit\^2/Hz Functional connectivity---Phase locking value (PLV): The value of PLV ranges from 0 to 1 Event related potentials in amplitude/μV

    Time frame: Day 1

Secondary outcomes

  1. Mini-mental state examination,MMSE

    Mini-mental state examination,MMSE: A score of 27-30: normal; Score \< 27: cognitive impairment.

    Time frame: Day 1

  2. Montreal Cognitive Assessment, MoCA

    Montreal Cognitive Assessment, MoCA: The total score of the scale is 30 points, and the test result shows that the normal value is ≥26 points.

    Time frame: Day 1

  3. Hamilton Depression Scale,HAMD

    Hamilton Depression Scale,HAMD: A total score of more than 35 May indicate severe depression.

    Time frame: Day 1

  4. Hamilton Anxiety Scale,HAMA

    Hamilton Anxiety Scale,HAMA: The total score ≥29, may be severe anxiety; ≥21 points, there must be obvious anxiety; ≥14 points, definitely have anxiety; More than 7 points, may have anxiety; If the score is less than 7, there is no anxiety symptom

    Time frame: Day 1

  5. Quick Inventory of Depressive Symptomatology Self-Report, QIDS-SR16

    Quick Inventory of Depressive Symptomatology Self-Report, QIDS-SR16: The total score is calculated on a scale of 0 to 27, with higher scores being associated with higher levels of depression.

    Time frame: Day 1

  6. Response time

    Recording their response times in seconds: The average reaction time of subjects in the facial expression recognition task to judge each facial expression picture.

    Time frame: Day 1

  7. Accuracy rates

    Recording their accuracy rates in % during the task: The average correct rate at which subjects judged each expression picture in the facial expression recognition task.

    Time frame: Day 1

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Feb 2027, 22 months later.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 22 months is close to that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2025
First posted
Apr 4, 2025
StartEst.
Mar 30, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
May 30, 2027
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06912191
Lead sponsor
The Second Affiliated Hospital of Kunming Medical University
Responsible party
Liqing Yao (Director, Department of Rehabilitation Medicine, the Second Affiliated Hospital of Kunming Medical University, The Second Affiliated Hospital of Kunming Medical University) — Principal investigator
First posted
Apr 4, 2025
Start date
Mar 30, 2025 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Apr 4, 2025

Study contacts

Zihan Chen
Contact
18208812691@163.com
+8618208812691

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion